The radio interview with Dr James Bradner provides brilliant...

The radio interview with Dr James Bradner provides brilliant insights into Myc and why Myc matters in the war on cancer. Bradner argues that unless the Myc problem is solved it will be difficult to cure cancer. Instead of accepting that Myc is undruggable, Bradner argues that our current drug discovery technologies are imperfect.

The reason for targeting Myc (or associated proteins) may be true for a whole range of cancers but the particular focus for Bradner has been myeloma.

Remember shareholders mild surprise when uploading the presentation from the recent AGM, that the oncology focus for Phylogica had changed from breast cancer to blood borne cancers including acute myeloid leukaemia. We were advised that Phylogica was 'engaging with key clinical players' and, thanks to Tony's astute observation in listening to the Hopkins presentation in September 2015, we understand that Phylogica is collaborating with Dana-Farber in AML.

Purely, speculative of course but could it be that the change in focus somehow ties-in with the collaboration with Dana-Farber?